XRpro Discovery of Decorporation Agents

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$600,000.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI079935-01A1
Award Id:
93358
Agency Tracking Number:
AI079935
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
278 DP Road Suite D, LOS ALAMOS, NM, 87544
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
147452275
Principal Investigator:
BENJAMINWARNER
(505) 412-2345
WARNER@CALDERA-PHARMACEUTICALS.COM
Business Contact:
BENJAMINWARNER
() -
court@cpsci.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Caldera Pharmaceuticals will use award-winning XRpro, a high throughput, label-free technology for producing nano-engineered radionuclide decorporation agents that are highly specific for their target radionuclide over similar elements. This proposal displays preliminary results showing specific decorporation agents for Sr(II) that do not bind Ca(II); Sr(II) is the only form of strontium (Sr) that is of concern for decorporation. Decorporation agents specific for element s such as Sr(II) and Co(II), which do not bind any essential metals, including Cu(II), Ca(II), Ni(II), Zn(II) are necessary. Emergency responders are currently forced to use non-selective chelators and blocking agents for radionuclide exposures. Sr-90 is e asily obtainable by terrorists who wish to do harm to US citizens, so Sr-90 decorporation is a very high national priority and treatments for Sr-90 exposures remain a critical need for the Strategic National Stockpile. Caldera's specific aims include using highly specific XRpro binding technologies to produce Sr decorporation agents. PUBLIC HEALTH RELEVANCE: Caldera Pharmaceuticals will use award-winning XRpro, a high throughput, label-free technology for producing nano-engineered radionuclide decorporation agents that are highly specific for their target radionuclide over similar elements. Emergency responders are currently forced to use non-selective chelators and blocking agents for radionuclide exposures. Sr-90 is easily obtainable by terrorists who wish to do harm to US citizens, so Sr-90 decorporation is a very high national priority and treatments for Sr-90 exposures remain a critical need for the Strategic National Stockpile.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government